[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362103-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362103-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","unraveling-line-1-retrotransposition-in-head-and-neck-squamous-cell-carcinoma-retrotest-method-supports-early-diagnosis","Unraveling LINE-1 retrotransposition in head and neck squamous cell carcinoma - RetroTest method supports early diagnosis","","LINE-1 (L1) retrotransposition has been linked to cancer, but the repetitive, dispersed nature of retrotransposons limits clinical identification and reduces patient-specific usefulness. This study introduces RetroTest, an efficient targeted-sequencing and bioinformatics pipeline to quantify L1 activation in tumor biopsies. Benchmarking supports high specificity and reliability, and an extensive HNSCC cohort shows unexpectedly early L1 activation during progression. Combined with mutational profiling in normal adjacent tissues, results support field cancerization, highlighting early L1 activation as a promising diagnostic biomarker.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/unraveling-line-1-retrotransposition-in-head-and-neck-squamous-cell-carcinoma-retrotest-method-supports-early-diagnosis/362103/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/unraveling-line-1-retrotransposition-in-head-and-neck-squamous-cell-carcinoma-retrotest-method-supports-early-diagnosis/362103.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the RetroTest method address in LINE-1 detection?","Question",{"text":63,"@type":64},"RetroTest targets the challenge that L1 retrotransposons are repetitive and dispersed, which hinders accurate activation estimates for clinical use.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was RetroTest validated before applying it to HNSCC?",{"text":68,"@type":64},"RetroTest benchmarking confirmed high specificity and reliability prior to its use in patient tumor biopsies.",{"name":70,"@type":61,"acceptedAnswer":71},"What key finding emerged about L1 activation in head-and-neck squamous cell carcinoma?",{"text":72,"@type":64},"L1 retrotransposition estimation showed surprisingly early activation during HNSCC progression, contrasting with the classical association with advanced stages.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362103,1790561295,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Unraveling LINE-1 retrotransposition in head and necksquamous cell carcinoma  \nJenifer Brea-Iglesias 1,2, Ana Oitabn 1,2, Sonia Zumalave2, Bernardo Rodriguez-Martin2*†,  \nMar a Gallardo-Gmez 1, Mart n Santamarina2, Ana Peque o-Valtierra2, Laura Juaneda-Magdalena 1, Ramn Garc a-Escudero3,4,5, Jos Luis Lpez-Cedr n6, Mximo Fraga7, Jos M. C. Tubio2 and Mnica Mart nez-Fernndez 1,2   \n1 Translational Oncology Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Estrada de Clara Campoamor, Vigo, Spain  \n2 Mobile Genomes Lab, Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidad de Santiago de Compostela, Santiago de Compostela, Spain  \n3 Molecular and Translational Oncology Division, CIEMAT (ed 70A), Madrid, Spain  \n4 Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain  \n5 Centro de Investigacin Biomdica en Red de Cncer (CIBERONC), Madrid, Spain  \n6 Department of Maxillofacial Surgery, University Hospital of A Coru~na, A Coru~na, Spain  \n7 Pathological Anatomy, Faculty of Medicine, University Clinical Hospital & Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain  \nKeywords  \nearly diagnosis biomarker; ﬁeldcancerization; head-and-neck squamous cell carcinoma; LINE-1; retrotransposition  \nCorrespondence  \nM. Martndez, Translational Oncology, Galicia Sur Health Research  \n􀀁  \nInstitute (IIS Galicia Sur), Hospital Alvaro Cunqueiro, Estrada de Clara Campoamor, 341, 36213 Vigo, Spain [E-mail:](E-mail: monica.martinez@iisgaliciasur.es)[ monica.martinez@iisgaliciasur.es](E-mail: monica.martinez@iisgaliciasur.es)  \nPresent address  \n*Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain  \n†Universitat Pompeu Fabra (UPF), Barcelona, Spain  \nJenifer Brea-Iglesias and Ana Oitabn contributed equally to this work.  \n(Received 27 September 2024, revised 22 April 2025, accepted 13 May 2025, available online 4 June 2025)  \ndoi:10 . 1002/1878-0261 .70063  \nThe relevant role of LINE-1 (L1) retrotransposition in cancer has been recurrently demonstrated in recent years. However, the repetitive nature of retrotransposons makes their identiﬁcation and detection inaccessible for clinical practice. Also, its clinical relevance for cancer patients is still limited. Here, we developed RetroTest, a new efﬁcient method to quantify L1 activation based on targeted sequencing and a sophisticated bioinformatic pipeline, allowing its application in tumor biopsies. Firstly, we performed RetroTest benchmarking to conﬁrm its high speciﬁcity and reliability. Then, we unraveled L1 activation in head-and-neck squamous cell carcinoma (HNSCC) according to an extensive patient cohort including all tumor stages. L1 retrotransposition estimation revealed a surprisingly early activation in HNSCC progression, contrary to its classical association with advanced stages. In addition, L1 activation together with genomic mutational proﬁling in normal adjacent tissues supported a ﬁeld cancerization process, a phenomenon where a tissue develops multiple patches of cells with genetic and/or epigenetic alterations, increasing the risk of cancer development in that area. Overall, our results underline an early L1 activation in HNSCC and ﬁeld characterization, raising L1 as a promising early diagnostic biomarker and supporting the importance of estimating L1 retrotransposition in clinical practice toward a more efﬁcient diagnosis in HNSCC.  \nAbbreviations  \nFFPE, formalin-ﬁxed parafﬁn-embedded; HNSCC, head-and-neck squamous cell carcinoma; LINE-1 (L1), long interspersed nuclear element; NAT, normal adjacent tissue; OS, overall survival; PFS, progression-free survival; PMBCs, peripheral blood mononuclear cells; TD2, orphan L1 transductions; TMB, tumor mutation burden; VAF, variant allele frequency; WGS, whole genome sequencing.  \nMolecular Oncology 19 (2025) 3769–3783 ª 2025 The Author(s) . Molecular Oncology published by John","cbCaiq2RqZDYbReJ","https://ap.wps.com/l/cbCaiq2RqZDYbReJ","pdf",1926821,15,"English","# Introduction\n## Background on LINE-1 and cancer relevance\n# RetroTest development\n## Targeted sequencing and bioinformatic pipeline\n# Benchmarking and validation\n## Specificity and reliability\n# L1 activation in HNSCC cohort\n## Early activation across tumor stages\n# Field cancerization support\n## Genomic profiling in normal adjacent tissues\n# Clinical implications\n## Early diagnostic biomarker potential","[{\"question\":\"What problem does the RetroTest method address in LINE-1 detection?\",\"answer\":\"RetroTest targets the challenge that L1 retrotransposons are repetitive and dispersed, which hinders accurate activation estimates for clinical use.\"},{\"question\":\"How was RetroTest validated before applying it to HNSCC?\",\"answer\":\"RetroTest benchmarking confirmed high specificity and reliability prior to its use in patient tumor biopsies.\"},{\"question\":\"What key finding emerged about L1 activation in head-and-neck squamous cell carcinoma?\",\"answer\":\"L1 retrotransposition estimation showed surprisingly early activation during HNSCC progression, contrasting with the classical association with advanced stages.\"}]","Unraveling LINE-1 retrotransposition in head and neck squamous cell carcinoma - RetroTest method supports early diagnosis | PDF",1790146478,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae14db2eb57a753a812f6bdd72db04c6.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4e68fb498218870d8c5345b805616a3.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31fe82a21bf23365ea95394d34ce8af6.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31e042dc1ddcfb7c584720e87fcb2aef.webp",980,1287]